Commonwealth Serum Laboratories Regulations (Amendment) (Cth)

Statutory Rules 1983 No. 231

–––––––

Commonwealth Serum Laboratories Regulations2 (Amendment)

I, THE GOVERNOR-GENERAL of the Commonwealth of Australia, acting with the advice of the Federal Executive Council, hereby make the following Regulations under the Commonwealth Serum Laboratories Act 1961.

Dated 23 February 1983.

N. M. STEPHEN

Governor-General

By His Excellency’s Command,

MICHAEL HODGMAN

Minister of State for the Capital Territory for and on behalf of the Minister of State for Health

––––––––––

Prescribed classes of pharmaceutical products

1. Regulation 3 of the Commonwealth Serum Laboratories Regulations is amended by adding at the end thereof the following sub-regulation:

“(2) Where, but for this sub-regulation, a class of pharmaceutical products specified in sub-regulation (1) would include a pharmaceutical product specified in regulation 4 that product is not included in that class.”.

2. The Commonwealth Serum Laboratories Regulations are amended by adding at the end thereof the following regulation:

Prescribed pharmaceutical products

“4. The following pharmaceutical products (in any form) are prescribed for the purposes of paragraph 19(1) (a) of the Commonwealth Serum Laboratories Act 1961:

(a) amiloride hydrochloride;

(b) amitriptyline embonate;

(c) amitriptyline hydrochloride;

(d) benztropine mesylate;

(e) chlorothiazide;

(f) cyproheptadine hydrochloride;

(g) diflunisal;

(h) ethacrynic acid;

(i) mixtures of hydrochlorothiazide and amiloride hydrochloride;

(j) hydrochlorothiazide;

(k) indomethacin;

(1) mixtures of levodopa and carbidopa;

(m) mecamylamine hydrochloride;

(n) methyldopa;

(o) probenecid;

(p) protriptyline hydrochloride;

(q) pyrazinamide;

(r) sulindac;

(s) thiabendazole;

(t) timolol maleate;

(u) mixtures of Vitamin B complex with glycerophosphates.”.

 

NOTES

1. Notified in the Commonwealth of Australia Gazette on 28 February 1983.

2. Statutory Rules 1981 No. 7.